Results 201 to 210 of about 1,962,745 (339)

Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade   +5 more
wiley   +1 more source

Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma. [PDF]

open access: yesHaematologica
Siegel A   +14 more
europepmc   +1 more source

Orofacial Tumours at the Oral and Maxillofacial Unit of Komfo Anokye Teaching Hospital: A 2‐Year Retrospective Study

open access: yesPublic Health Challenges, Volume 5, Issue 2, June 2026.
This retrospective study of 204 patients in Ghana identifies the mandible as the most common tumour site. Findings reveal a significant association between age and tumour type, with benign lesions predominating in younger adults and malignancies peaking in the elderly, emphasizing the need for age‐specific screening.
Gift Obiageri Maduagwu   +6 more
wiley   +1 more source

Mpox Awareness and Infection Control Practices Among Hospital Nurses and Healthcare Workers in Bangladesh

open access: yesPublic Health Challenges, Volume 5, Issue 2, June 2026.
This study summarizes the KAP measures regarding Mpox among healthcare workers in Bangladesh. A total of 110 participants were included, with 60.9% having prior awareness, mainly through social media. Overall, 47.3% demonstrated good knowledge, whereas positive attitudes (86.4%) and appropriate practices (82.7%) were observed.
Hemayet Hossain   +8 more
wiley   +1 more source

Lessons from the outbreak of Marburg virus. [PDF]

open access: yes, 2005
Borchert, Matthias   +2 more
core   +1 more source

Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults—A Pilot Study

open access: yesAging Cell, Volume 25, Issue 6, June 2026.
Can we boost vaccine responses in older adults? In a double‐blind, randomised, placebo‐controlled pilot study (n = 40, > 65 years), spermidine supplementation (6 mg/day, 13 weeks) was safe and significantly improved immune responses following a 3rd SARS‐CoV‐2 vaccine dose.
Ghada Alsaleh   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy